Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety

MP Cicalese, F Ferrua, L Castagnaro, K Rolfe, E De Boever, RR Reinhardt, J Appleby, MG Roncarolo, A Aiuti

Research output: Contribution to journalArticle

Abstract

Loss of adenosine deaminase activity leads to severe combined immunodeficiency (ADA-SCID); production and function of T, B, and natural killer (NK) cells are impaired. Gene therapy (GT) with an autologous CD34 + -enriched cell fraction that contains CD34 + cells transduced with a retroviral vector encoding the human ADA cDNA sequence leads to immune reconstitution in most patients. Here, we report short- and medium-term safety analyses from 18 patients enrolled as part of single-arm, open-label studies or compassionate use programs. Survival was 100% with a median of 6.9 years follow-up (range, 2.3 to 13.4 years). Adverse events were mostly grade 1 or grade 2 and were reported by all 18 patients following GT. Thirty-nine serious adverse events (SAEs) were reported by 15 of 18 patients; no SAEs were considered related to GT. The most common adverse events reported post-GT include upper respiratory tract infection, gastroenteritis, rhinitis, bronchitis, oral candidiasis, cough, neutropenia, diarrhea, and pyrexia. Incidence rates for all of these events were highest during pre-treatment, treatment, and/or 3-month follow-up and then declined over medium-term follow-up. GT did not impact the incidence of neurologic/hearing impairments. No event indicative of leukemic transformation was reported. In 2016 the gene therapy, Strimvelis was approved for the treatment of patients with ADA-SCID for whom there is no suitable bone marrow donor. In this issue of Molecular Therapy, Aiuti et al. provide detailed safety data for treated patients. All patients are alive and without evidence of leukemic transformation. © 2018 The Authors
Original languageEnglish
Pages (from-to)917-931
Number of pages15
JournalMolecular Therapy
Volume26
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Genetic Therapy
Safety
Severe Combined Immunodeficiency
Adenosine Deaminase
Compassionate Use Trials
Oral Candidiasis
Natural Killer T-Cells
Bronchitis
Incidence
Gastroenteritis
Therapeutics
Rhinitis
Severe combined immunodeficiency due to adenosine deaminase deficiency
Neutropenia
Hearing Loss
Cough
Respiratory Tract Infections
Nervous System
Diarrhea
Fever

Cite this

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. / Cicalese, MP; Ferrua, F; Castagnaro, L; Rolfe, K; De Boever, E; Reinhardt, RR; Appleby, J; Roncarolo, MG; Aiuti, A.

In: Molecular Therapy, Vol. 26, No. 3, 2018, p. 917-931.

Research output: Contribution to journalArticle

Cicalese, MP ; Ferrua, F ; Castagnaro, L ; Rolfe, K ; De Boever, E ; Reinhardt, RR ; Appleby, J ; Roncarolo, MG ; Aiuti, A. / Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. In: Molecular Therapy. 2018 ; Vol. 26, No. 3. pp. 917-931.
@article{d3d7ceab63794148af858e6eda0f6794,
title = "Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety",
abstract = "Loss of adenosine deaminase activity leads to severe combined immunodeficiency (ADA-SCID); production and function of T, B, and natural killer (NK) cells are impaired. Gene therapy (GT) with an autologous CD34 + -enriched cell fraction that contains CD34 + cells transduced with a retroviral vector encoding the human ADA cDNA sequence leads to immune reconstitution in most patients. Here, we report short- and medium-term safety analyses from 18 patients enrolled as part of single-arm, open-label studies or compassionate use programs. Survival was 100{\%} with a median of 6.9 years follow-up (range, 2.3 to 13.4 years). Adverse events were mostly grade 1 or grade 2 and were reported by all 18 patients following GT. Thirty-nine serious adverse events (SAEs) were reported by 15 of 18 patients; no SAEs were considered related to GT. The most common adverse events reported post-GT include upper respiratory tract infection, gastroenteritis, rhinitis, bronchitis, oral candidiasis, cough, neutropenia, diarrhea, and pyrexia. Incidence rates for all of these events were highest during pre-treatment, treatment, and/or 3-month follow-up and then declined over medium-term follow-up. GT did not impact the incidence of neurologic/hearing impairments. No event indicative of leukemic transformation was reported. In 2016 the gene therapy, Strimvelis was approved for the treatment of patients with ADA-SCID for whom there is no suitable bone marrow donor. In this issue of Molecular Therapy, Aiuti et al. provide detailed safety data for treated patients. All patients are alive and without evidence of leukemic transformation. {\circledC} 2018 The Authors",
author = "MP Cicalese and F Ferrua and L Castagnaro and K Rolfe and {De Boever}, E and RR Reinhardt and J Appleby and MG Roncarolo and A Aiuti",
year = "2018",
doi = "10.1016/j.ymthe.2017.12.022",
language = "English",
volume = "26",
pages = "917--931",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety

AU - Cicalese, MP

AU - Ferrua, F

AU - Castagnaro, L

AU - Rolfe, K

AU - De Boever, E

AU - Reinhardt, RR

AU - Appleby, J

AU - Roncarolo, MG

AU - Aiuti, A

PY - 2018

Y1 - 2018

N2 - Loss of adenosine deaminase activity leads to severe combined immunodeficiency (ADA-SCID); production and function of T, B, and natural killer (NK) cells are impaired. Gene therapy (GT) with an autologous CD34 + -enriched cell fraction that contains CD34 + cells transduced with a retroviral vector encoding the human ADA cDNA sequence leads to immune reconstitution in most patients. Here, we report short- and medium-term safety analyses from 18 patients enrolled as part of single-arm, open-label studies or compassionate use programs. Survival was 100% with a median of 6.9 years follow-up (range, 2.3 to 13.4 years). Adverse events were mostly grade 1 or grade 2 and were reported by all 18 patients following GT. Thirty-nine serious adverse events (SAEs) were reported by 15 of 18 patients; no SAEs were considered related to GT. The most common adverse events reported post-GT include upper respiratory tract infection, gastroenteritis, rhinitis, bronchitis, oral candidiasis, cough, neutropenia, diarrhea, and pyrexia. Incidence rates for all of these events were highest during pre-treatment, treatment, and/or 3-month follow-up and then declined over medium-term follow-up. GT did not impact the incidence of neurologic/hearing impairments. No event indicative of leukemic transformation was reported. In 2016 the gene therapy, Strimvelis was approved for the treatment of patients with ADA-SCID for whom there is no suitable bone marrow donor. In this issue of Molecular Therapy, Aiuti et al. provide detailed safety data for treated patients. All patients are alive and without evidence of leukemic transformation. © 2018 The Authors

AB - Loss of adenosine deaminase activity leads to severe combined immunodeficiency (ADA-SCID); production and function of T, B, and natural killer (NK) cells are impaired. Gene therapy (GT) with an autologous CD34 + -enriched cell fraction that contains CD34 + cells transduced with a retroviral vector encoding the human ADA cDNA sequence leads to immune reconstitution in most patients. Here, we report short- and medium-term safety analyses from 18 patients enrolled as part of single-arm, open-label studies or compassionate use programs. Survival was 100% with a median of 6.9 years follow-up (range, 2.3 to 13.4 years). Adverse events were mostly grade 1 or grade 2 and were reported by all 18 patients following GT. Thirty-nine serious adverse events (SAEs) were reported by 15 of 18 patients; no SAEs were considered related to GT. The most common adverse events reported post-GT include upper respiratory tract infection, gastroenteritis, rhinitis, bronchitis, oral candidiasis, cough, neutropenia, diarrhea, and pyrexia. Incidence rates for all of these events were highest during pre-treatment, treatment, and/or 3-month follow-up and then declined over medium-term follow-up. GT did not impact the incidence of neurologic/hearing impairments. No event indicative of leukemic transformation was reported. In 2016 the gene therapy, Strimvelis was approved for the treatment of patients with ADA-SCID for whom there is no suitable bone marrow donor. In this issue of Molecular Therapy, Aiuti et al. provide detailed safety data for treated patients. All patients are alive and without evidence of leukemic transformation. © 2018 The Authors

U2 - 10.1016/j.ymthe.2017.12.022

DO - 10.1016/j.ymthe.2017.12.022

M3 - Article

VL - 26

SP - 917

EP - 931

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -